Plaquetec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood

  • Post author:
  • Post published:
  • Post category:uncategorized

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), based at the Babraham Research Campus, and the Flow Cytometry Facility at the Babraham Institute today announced a…

Continue ReadingPlaquetec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

  • Post author:
  • Post published:
  • Post category:uncategorized

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to…

Continue ReadingCalluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

CN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

  • Post author:
  • Post published:
  • Post category:uncategorized

CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.

Continue ReadingCN Bio and Altis Biosystems partner to develop next-generation human Gut/Liver in vitro model for advanced ADME studies

What are the capabilities of a commercially available p-tau217 immunoassay to identify Alzheimer disease pathophysiology?

  • Post author:
  • Post published:
  • Post category:uncategorized

Researchers determined the utility of a novel and commercially available immunoassay for plasma phosphorylated tau 217 to detect Alzheimer's Disease pathology and evaluate reference ranges for abnormal amyloid β and…

Continue ReadingWhat are the capabilities of a commercially available p-tau217 immunoassay to identify Alzheimer disease pathophysiology?